ArticleInvestigational new drugs2020

A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies.

Noboru Yamamoto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.